Cargando…
Cytosolic delivery of the immunological adjuvant Poly I:C and cytotoxic drug crystals via a carrier-free strategy significantly amplifies immune response
Co-delivery of chemotherapeutics and immunostimulant or chemoimmunotherapy is an emerging strategy in cancer therapy. The precise control of the targeting and release of agents is critical in this methodology. This article proposes the asynchronous release of the chemotherapeutic agents and immunost...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546930/ https://www.ncbi.nlm.nih.gov/pubmed/34729315 http://dx.doi.org/10.1016/j.apsb.2021.03.014 |
_version_ | 1784590284820054016 |
---|---|
author | Du, Xiaoqing Hou, Yuqi Huang, Jia Pang, Yan Ruan, Chenlu Wu, Wei Xu, Chenjie Zhang, Hongwei Yin, Lifang He, Wei |
author_facet | Du, Xiaoqing Hou, Yuqi Huang, Jia Pang, Yan Ruan, Chenlu Wu, Wei Xu, Chenjie Zhang, Hongwei Yin, Lifang He, Wei |
author_sort | Du, Xiaoqing |
collection | PubMed |
description | Co-delivery of chemotherapeutics and immunostimulant or chemoimmunotherapy is an emerging strategy in cancer therapy. The precise control of the targeting and release of agents is critical in this methodology. This article proposes the asynchronous release of the chemotherapeutic agents and immunostimulants to realize the synergistic effect between chemotherapy and immunotherapy. To obtain a proof-of-concept, a co-delivery system was prepared via a drug-delivering-drug (DDD) strategy for cytosolic co-delivery of Poly I:C, a synthetic dsRNA analog to activate RIG-I signaling, and PTX, a commonly used chemotherapeutics, in which pure PTX nanorods were sequentially coated with Poly I:C and mannuronic acid via stimulating the RIG-I signaling axis. The co-delivery system with a diameter of 200 nm enables profound immunogenicity of cancer cells, exhibiting increased secretion of cytokines and chemokines, pronounced immune response in vivo, and significant inhibition of tumor growth. Also, we found that intracellularly sustained release of cytotoxic agents could elicit the immunogenicity of cancer cells. Overall, the intracellular asynchronous release of chemotherapeutics and immunomodulators is a promising strategy to promote the immunogenicity of cancer cells and augment the antitumor immune response. |
format | Online Article Text |
id | pubmed-8546930 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-85469302021-11-01 Cytosolic delivery of the immunological adjuvant Poly I:C and cytotoxic drug crystals via a carrier-free strategy significantly amplifies immune response Du, Xiaoqing Hou, Yuqi Huang, Jia Pang, Yan Ruan, Chenlu Wu, Wei Xu, Chenjie Zhang, Hongwei Yin, Lifang He, Wei Acta Pharm Sin B Original Article Co-delivery of chemotherapeutics and immunostimulant or chemoimmunotherapy is an emerging strategy in cancer therapy. The precise control of the targeting and release of agents is critical in this methodology. This article proposes the asynchronous release of the chemotherapeutic agents and immunostimulants to realize the synergistic effect between chemotherapy and immunotherapy. To obtain a proof-of-concept, a co-delivery system was prepared via a drug-delivering-drug (DDD) strategy for cytosolic co-delivery of Poly I:C, a synthetic dsRNA analog to activate RIG-I signaling, and PTX, a commonly used chemotherapeutics, in which pure PTX nanorods were sequentially coated with Poly I:C and mannuronic acid via stimulating the RIG-I signaling axis. The co-delivery system with a diameter of 200 nm enables profound immunogenicity of cancer cells, exhibiting increased secretion of cytokines and chemokines, pronounced immune response in vivo, and significant inhibition of tumor growth. Also, we found that intracellularly sustained release of cytotoxic agents could elicit the immunogenicity of cancer cells. Overall, the intracellular asynchronous release of chemotherapeutics and immunomodulators is a promising strategy to promote the immunogenicity of cancer cells and augment the antitumor immune response. Elsevier 2021-10 2021-03-12 /pmc/articles/PMC8546930/ /pubmed/34729315 http://dx.doi.org/10.1016/j.apsb.2021.03.014 Text en © 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Du, Xiaoqing Hou, Yuqi Huang, Jia Pang, Yan Ruan, Chenlu Wu, Wei Xu, Chenjie Zhang, Hongwei Yin, Lifang He, Wei Cytosolic delivery of the immunological adjuvant Poly I:C and cytotoxic drug crystals via a carrier-free strategy significantly amplifies immune response |
title | Cytosolic delivery of the immunological adjuvant Poly I:C and cytotoxic drug crystals via a carrier-free strategy significantly amplifies immune response |
title_full | Cytosolic delivery of the immunological adjuvant Poly I:C and cytotoxic drug crystals via a carrier-free strategy significantly amplifies immune response |
title_fullStr | Cytosolic delivery of the immunological adjuvant Poly I:C and cytotoxic drug crystals via a carrier-free strategy significantly amplifies immune response |
title_full_unstemmed | Cytosolic delivery of the immunological adjuvant Poly I:C and cytotoxic drug crystals via a carrier-free strategy significantly amplifies immune response |
title_short | Cytosolic delivery of the immunological adjuvant Poly I:C and cytotoxic drug crystals via a carrier-free strategy significantly amplifies immune response |
title_sort | cytosolic delivery of the immunological adjuvant poly i:c and cytotoxic drug crystals via a carrier-free strategy significantly amplifies immune response |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546930/ https://www.ncbi.nlm.nih.gov/pubmed/34729315 http://dx.doi.org/10.1016/j.apsb.2021.03.014 |
work_keys_str_mv | AT duxiaoqing cytosolicdeliveryoftheimmunologicaladjuvantpolyicandcytotoxicdrugcrystalsviaacarrierfreestrategysignificantlyamplifiesimmuneresponse AT houyuqi cytosolicdeliveryoftheimmunologicaladjuvantpolyicandcytotoxicdrugcrystalsviaacarrierfreestrategysignificantlyamplifiesimmuneresponse AT huangjia cytosolicdeliveryoftheimmunologicaladjuvantpolyicandcytotoxicdrugcrystalsviaacarrierfreestrategysignificantlyamplifiesimmuneresponse AT pangyan cytosolicdeliveryoftheimmunologicaladjuvantpolyicandcytotoxicdrugcrystalsviaacarrierfreestrategysignificantlyamplifiesimmuneresponse AT ruanchenlu cytosolicdeliveryoftheimmunologicaladjuvantpolyicandcytotoxicdrugcrystalsviaacarrierfreestrategysignificantlyamplifiesimmuneresponse AT wuwei cytosolicdeliveryoftheimmunologicaladjuvantpolyicandcytotoxicdrugcrystalsviaacarrierfreestrategysignificantlyamplifiesimmuneresponse AT xuchenjie cytosolicdeliveryoftheimmunologicaladjuvantpolyicandcytotoxicdrugcrystalsviaacarrierfreestrategysignificantlyamplifiesimmuneresponse AT zhanghongwei cytosolicdeliveryoftheimmunologicaladjuvantpolyicandcytotoxicdrugcrystalsviaacarrierfreestrategysignificantlyamplifiesimmuneresponse AT yinlifang cytosolicdeliveryoftheimmunologicaladjuvantpolyicandcytotoxicdrugcrystalsviaacarrierfreestrategysignificantlyamplifiesimmuneresponse AT hewei cytosolicdeliveryoftheimmunologicaladjuvantpolyicandcytotoxicdrugcrystalsviaacarrierfreestrategysignificantlyamplifiesimmuneresponse |